StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
July 24, 2024 7:43 AM
SAGE Therapeutics (NASDAQ: SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails- SAGE-324 (BIIB124) did not demonstrate ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Momentum Movers
Next Articles
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM
Sage Therapeutics stock sinks after drug study failed
July 24, 2024 8:15 AM
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
July 24, 2024 6:32 AM
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
July 24, 2024 6:30 AM
